Polyethylene Glycol 3350
RxNorm Crosswalk NDC 0722-6921

View RxNorm Concepts, RxCUIs, and Term Type mappings for this NDC

RxNorm Mapping Clinical Concepts

This drug is included in the RxNorm Current Prescribable Content, a subset of RxNorm that includes all drugs available for prescription in the United States.

The product Polyethylene Glycol 3350 (NDC 0722-6921) is cross-mapped to the RxNorm terminology system to ensure clinical interoperability. This formulation is linked to a unique clinical concept (RxCUI 876193). By anchoring Nexgen Pharma, Inc.'s product data to these standardized identifiers, healthcare systems can maintain accurate medication records, safely automate e-prescribing, and streamline pharmacy workflows.

The following clinical concept cards detail the semantic term types (TTY), prescribable names, and synonymous clinical strings as defined by the National Library of Medicine (NLM).

SCDPrescribable
Featured Concept

polyethylene glycol 3350 17000 MG Powder for Oral Solution
(RxCUI 876193)

Semantic Clinical Drug

Semantic Clinical Drug: The clinical gold standard representing the Generic Name + Strength + Dosage Form.

Understanding RxNorm Mapping for Polyethylene Glycol 3350

RxNorm is a normalized naming system developed by the National Library of Medicine (NLM) to bridge the gap between different drug terminologies. By mapping NDC 0722-6921 to RxCUI 876193, this page provides the standardized "source of truth" required for hospital systems, e-prescribing software, and pharmacy benefit managers (PBMs) to communicate without errors.

Term Type (TTY) Legend for This Page

The clinical cards above utilize specific Term Types (TTY) to define the granularity of the drug concept:

  • PSN Prescribable Name: The standardized name preferred by electronic prescribing (eRx) applications for display.
  • SCD Semantic Clinical Drug: The clinical gold standard representing the Generic Name + Strength + Dosage Form.
  • SY Synonym: An alternative clinical name or alias provided for search and retrieval clarity.

* Please review the full disclaimer at the bottom of this page.